Loading…
Lobbying Spend
—
Filings
14
Firms Hired
1
Active Period
2020–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Positioning the Election Assistance Commission for the Future Act of 2023
2023 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · fourth_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · fourth_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · third_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · third_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · second_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · second_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2021 · fourth_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2021 · fourth_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Facilitating Innovative Nuclear Diagnostics Act of 2021
2021 · third_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: H.R. 4479
Facilitating Innovative Nuclear Diagnostics Act of 2021
2021 · third_quarter · Firm: KING & SPALDING LLP
Advocacy on Medicare coverage of Amyloid PET, outpatient package payment and H.R. 4479 (117) and S.2609 (117), Facilitating Innovative Nuclear Diagnostics Act of 2021
Client expense: — · Firm income: $80,000
Matched citations: S.2609
Housing Is a Human Right Act of 2021
2021 · second_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772 (116) and Medicare coverage of Amyloid PET
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3772
Housing Is a Human Right Act of 2021
2021 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: $80,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · fourth_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · third_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · second_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3772
Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019
2020 · first_quarter · Firm: KING & SPALDING LLP
Advocacy on outpatient package payment and H.R. 3772
Client expense: — · Firm income: —
Matched citations: H.R. 3772
Source: Senate LDA